Peritoneal Mesothelioma

What is Peritoneal Mesothelioma?

Peritoneal mesothelioma is a rare cancer that forms in the peritoneum, the thin membrane lining the abdominal cavity and covering the surfaces of the organs within it. It accounts for roughly 10 to 20 percent of all mesothelioma diagnoses and is almost always caused by asbestos exposure, typically decades before the first symptoms appear.

It is also, in a meaningful sense, a different disease from what peritoneal mesothelioma was twenty years ago. The development of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) — a procedure that surgically removes all visible tumor from the abdominal cavity and then bathes the peritoneal surfaces with heated chemotherapy — has transformed outcomes for eligible patients. Median survival after CRS-HIPEC at experienced centers now exceeds three years. Some patients with favorable disease characteristics are living five, ten, or more years after treatment. Those timelines reflect what aggressive, specialized treatment can achieve in the right patient at the right treatment center.

The key phrase is "right treatment center." Peritoneal mesothelioma is rare enough that most oncologists will encounter only a handful of cases in their careers. CRS-HIPEC requires not just a skilled surgeon but an entire institutional infrastructure. The gap in outcomes between high-volume academic centers and community hospitals treating this disease has been measured directly, in a study of this specific disease, and it is substantial: treatment at an academic center doubles the median survival time. Where you are treated is therefore not a secondary consideration.

For the full treatment discussion of CRS-HIPEC, chemotherapy, immunotherapy, emerging therapies, and costs, see our dedicated treatment page:

Peritoneal Mesothelioma: Treatment Options, Costs, and Prognosis in 2026

Learn about all forms of mesothelioma.

Symptoms of Peritoneal Mesothelioma

Peritoneal mesothelioma is one of the most frequently misdiagnosed cancers in medicine because its symptoms are almost identical to those of far more common conditions. Abdominal pain gets attributed to irritable bowel syndrome. Bloating is assumed to be dietary. Unexplained weight loss prompts investigation of the gastrointestinal tract. Fluid buildup in the abdomen is evaluated for liver disease, ovarian cancer, or heart failure long before peritoneal mesothelioma enters the differential diagnosis.

In one national study, only 25.8% of patients were referred for surgical evaluation based on initial clinical suspicion of peritoneal mesothelioma. In a study of women specifically, 15% were diagnosed incidentally, during surgery performed for a presumed gynecological condition that turned out to be something else entirely.

If you have a history of asbestos exposure, that context should change how you and your doctor evaluate the symptoms below. Tell your doctor about your asbestos exposure history explicitly, even if it was decades ago and even if the contact seemed minor. It is one of the most important pieces of information they can have.

Ascites (Abdominal Fluid Buildup)

Ascites is an abnormal accumulation of fluid in the peritoneal cavity and is one of the most common presenting findings in peritoneal mesothelioma — often what finally sends patients to the doctor. As tumors grow along the peritoneal surfaces, they disrupt the normal fluid balance maintained by the peritoneum, causing fluid to accumulate in the abdominal cavity, producing visible and palpable abdominal swelling, a sensation of heaviness or fullness, and in some patients significant discomfort.

When ascites occurs in a patient with a history of asbestos exposure, peritoneal mesothelioma should be on the differential diagnosis from the first evaluation, not after other explanations have been exhausted.

Abdominal Pain or Discomfort

Persistent abdominal pain is one of the earliest and most commonly reported symptoms. It may be diffuse or more localized, depending on where tumor deposits are concentrated. Early in the disease, it is often dull and intermittent. As the disease progresses, pain typically becomes more constant and severe. Pain that is persistent, worsening, and unresponsive to dietary changes, acid suppression, or motility agents warrants more thorough investigation, particularly in someone with asbestos exposure history.

Abdominal Swelling or Bloating

Beyond the swelling caused by ascites, patients often report a more generalized sense of abdominal distension that does not track with eating or bowel habits. This reflects the cumulative bulk of tumor deposits distributed across the peritoneal surfaces, the omentum, and the surfaces of abdominal organs. Patients frequently describe feeling full even when they have not eaten, or noticing that clothing fits differently over a period of weeks or months.

Unexplained Weight Loss

Significant, unintended weight loss without changes in diet or physical activity is a systemic warning sign in peritoneal mesothelioma as in most cancers. It is driven partly by the metabolic demands the tumor places on the body, and partly by the gastrointestinal consequences of the disease: early satiety, nausea, altered bowel habits, and reduced appetite all reduce caloric intake at the same time the cancer is increasing caloric demand.

Nausea, Early Satiety, and Digestive Changes

As tumor deposits grow on the peritoneal surfaces surrounding the stomach, small bowel, and colon, they can compress or invade these structures, producing symptoms that are easy to misattribute to primary gastrointestinal disease. Nausea without obvious cause, a feeling of fullness after eating only small amounts, changes in bowel habits including new-onset constipation, and intermittent episodes that resemble partial bowel obstruction are all consistent with peritoneal mesothelioma.

Fatigue and Weakness

Profound and persistent fatigue is a common symptom reflecting the systemic effects of malignancy: chronic inflammation, altered metabolism, poor nutritional absorption, and the immune system's sustained effort to respond to the tumor.

New or Worsening Hernia

Some patients develop a new hernia or notice worsening of a pre-existing one — particularly umbilical or inguinal hernias. Increasing intra-abdominal pressure from ascites and tumor bulk can push tissue through weak points in the abdominal wall.

Fever and Night Sweats

Some patients experience low-grade fevers or night sweats reflecting the sustained inflammatory state produced by peritoneal tumor burden. In combination with abdominal findings and in the context of asbestos exposure, they contribute to the overall clinical picture that warrants investigation.

When to See a Doctor

If you are experiencing persistent abdominal symptoms and have any history of asbestos exposure, the combination deserves prompt and specific evaluation. Ask your physician directly: "Could this be related to asbestos exposure?" Request cross-sectional imaging: a contrast-enhanced CT scan of the abdomen and pelvis is the appropriate first-line tool.

Early diagnosis matters enormously in peritoneal mesothelioma. Patients whose disease is identified at low tumor burden are far more likely to be candidates for CRS-HIPEC. The difference between a low-PCI surgical candidate and a high-PCI non-surgical candidate is often a matter of how quickly the correct diagnosis was reached.

Our firm offers free asbestos health evaluations for individuals with symptoms and a history of exposure. We can help connect you with diagnostic resources and explain your legal and medical options at no cost and with no obligation.

What Causes Peritoneal Mesothelioma?

Peritoneal mesothelioma has one overwhelming cause: asbestos exposure. The World Health Organization, the CDC, the National Institute for Occupational Safety and Health, and every major public health authority agree: all commercially used forms of asbestos can cause mesothelioma. There is no known safe level of exposure, and no established threshold below which asbestos contact is harmless.

How Asbestos Fibers Reach the Peritoneum

Inhalation and lymphatic transport. The most common route begins the same way pleural mesothelioma does: asbestos fibers are inhaled and reach the deep lung tissue. From there, fibers can enter the lymphatic system, which connects the chest to the abdominal cavity. Fibers carried by lymphatic flow can be deposited in the peritoneal lining and the omentum, triggering the same cascade of chronic inflammation, cellular damage, and genetic mutation that drives mesothelioma wherever it develops.

Ingestion and gastrointestinal transit. Asbestos fibers can also be swallowed directly through contaminated food or water, or through contact with asbestos dust on hands or surfaces. Additionally, fibers that have been inhaled and trapped in the upper airways are moved upward by the mucociliary system and swallowed. Once ingested, fibers can pass through the wall of the gastrointestinal tract and enter the peritoneal cavity directly, or be absorbed and transported to the peritoneum through the gastrointestinal lymphatic network.

Perineal migration from talc exposure. In women, a distinct pathway exists through the reproductive tract. Talc and asbestos are geologically related minerals that frequently occur together, and historical talcum powder products — including widely used consumer brands like Johnson & Johnson — have been found to contain asbestos contamination. Long-term perineal use of talcum powder can allow fibers to migrate through the reproductive tract and into the peritoneal cavity, where they cause the same inflammatory cascade that drives mesothelioma through other exposure routes. This pathway is specifically associated with peritoneal disease in women without occupational or secondary asbestos exposure and is discussed in detail in our dedicated page on peritoneal mesothelioma in women.

What happens once fibers arrive. Regardless of how asbestos fibers reach the peritoneum, the body's immune system mounts a sustained response against the embedded fibers, but because it cannot break down or expel asbestos, the inflammation never resolves. Chronic inflammation repeatedly injures the surrounding mesothelial cells. Over time, the accumulated damage reaches the cell's DNA, disrupting the tumor suppressor genes that regulate cell growth and repair. When those regulatory mechanisms fail, cells that should stop dividing keep dividing. Eventually, that process produces a tumor. The entire sequence from first exposure to cancer diagnosis typically takes 20 to 60 years.

Why Even Brief Exposure Can Be Enough

The medical consensus is clear: there is no established threshold of exposure below which asbestos is safe. Duration and intensity of exposure affect the statistical probability of developing mesothelioma — heavier, longer exposure carries higher risk — but they do not determine the possibility. Some patients who develop peritoneal mesothelioma had only brief or incidental contact with asbestos: a few months on a job site, secondary exposure through a family member's work clothes, or years of cosmetic talc use they never connected to asbestos at all.

How People Were Typically Exposed

Occupational exposure is the most common route. Construction workers, shipyard workers, insulators, pipefitters, electricians, plumbers, boilermakers, auto mechanics, and workers in oil refineries, power plants, steel mills, textile factories, and paper manufacturing facilities regularly encountered asbestos-containing materials throughout the mid-twentieth century.

Learn more about asbestos exposure by occupation.

Secondary (take-home) exposure affected family members of workers who carried asbestos fibers home on their clothing, skin, hair, and tools. Many women diagnosed with peritoneal mesothelioma today have no direct occupational exposure history; their only contact with asbestos came through a husband or father who worked with it for decades.

Learn more about secondary and take-home asbestos exposure.

Military service exposed hundreds of thousands of veterans to asbestos, particularly those who served in the Navy and in naval shipyards where asbestos insulation was used pervasively in ship construction and maintenance. Veterans with peritoneal mesothelioma may qualify for VA disability benefits and healthcare in addition to civil legal claims.

Learn more about asbestos exposure in the military.

Asbestos-containing products were incorporated into thousands of commercial and industrial materials across the twentieth century, with pipe insulation, floor and ceiling tiles, joint compound, roofing felt, gaskets, friction materials, spray-applied fireproofing, boiler coverings, and cement board among them. Identifying which products were present at specific job sites is one of the most important functions of the exposure reconstruction we perform for every client.

Explore asbestos-containing products.

Industry-wide ambient exposure affected workers who never personally handled asbestos but worked in environments where it was pervasive — such as shipyards, refineries, power plants, and large manufacturing facilities where asbestos dust coated surfaces, hung in the air, and contaminated clothing and equipment throughout the facility.

Learn more about industry-specific asbestos exposure.

Cosmetic talc exposure is a peritoneal-specific pathway. Women who used talcum powder products for personal hygiene over many years may have been unknowingly exposed to asbestos through contaminated talc, and that exposure may be the basis for both a peritoneal mesothelioma diagnosis and a legal claim against the manufacturers of those products.

Exposure From Decades Ago Is Very Relevant

Because peritoneal mesothelioma has a latency period of 20 to 60 years, many patients are unaware they were ever exposed to asbestos in a legally relevant sense. The job held in the 1970s, the husband's work clothes laundered for thirty years, the talcum powder used daily for decades — none of these seemed dangerous at the time, and none of them were labeled as asbestos hazards. They were, and the companies that knew that chose not to say so.

Reconstructing that exposure history is the foundation of every asbestos legal claim. It is work that requires institutional knowledge, proprietary exposure databases, and investigative resources. It is also work we do routinely, often recovering exposure histories from job sites and product lines that patients themselves only partially remember.

How Peritoneal Mesothelioma Is Diagnosed

Peritoneal mesothelioma is one of the most frequently misdiagnosed cancers in medicine. The diagnostic process almost always involves multiple steps across multiple specialties, and it typically requires a combination of imaging, fluid analysis, tissue biopsy, and specialized pathological analysis before a definitive diagnosis can be reached.

Speed matters here in a way it does in few other cancers. Peritoneal mesothelioma is staged not by TNM criteria but by the Peritoneal Cancer Index — a measure of how widely tumor has spread across the abdominal cavity. Patients whose disease is identified at low tumor burden have meaningfully better access to CRS-HIPEC. Every month of diagnostic delay is a month in which tumor burden may be increasing and surgical candidacy narrowing.

Imaging: Where the Diagnostic Process Begins

Contrast-enhanced CT of the abdomen and pelvis is the standard first-line imaging study. CT can identify ascites, peritoneal thickening, omental involvement, and discrete tumor nodules distributed across the peritoneal surfaces. It also provides an initial estimate of tumor burden, though CT consistently underestimates the true extent of peritoneal disease — particularly small-volume disease on bowel surfaces and the small bowel mesentery — compared to what surgeons find at laparoscopy.

Diffusion-weighted MRI provides superior characterization of small bowel involvement, which is both one of the most important variables in assessing CRS-HIPEC candidacy and one that CT frequently underestimates. At most major peritoneal mesothelioma centers, MRI is a routine component of the preoperative workup rather than a supplemental study.

PET-CT adds metabolic information to anatomical imaging. In peritoneal mesothelioma, PET-CT is most useful for detecting extra-abdominal disease that would affect surgical planning, evaluating lymph node involvement, and identifying sites of high metabolic activity not clearly visualized on CT alone. Small-volume peritoneal deposits below 5 millimeters may not produce sufficient metabolic signal. PET-CT is used selectively at major centers when the extent of disease is uncertain.

No combination of CT, MRI, and PET-CT can definitively diagnose peritoneal mesothelioma. Imaging identifies findings consistent with the diagnosis and guides the subsequent biopsy. Only a biopsy can confirm the diagnosis.

Paracentesis and Ascitic Fluid Analysis

When ascites is present, draining the fluid through paracentesis typically serves two purposes: symptom relief and diagnostic sampling. Fewer than 30% of cases are diagnosable from fluid alone, and even when mesothelioma cells are identified, cytological findings cannot reliably determine the histological subtype — information that is essential for treatment planning and surgical candidacy assessment. Tissue biopsy is required in virtually every case.

Biopsy: The Path to a Definitive Diagnosis

Diagnostic laparoscopy is the preferred biopsy approach at most major peritoneal mesothelioma centers. It is simultaneously the best way to confirm the diagnosis and the best way to assess the Peritoneal Cancer Index. Using small camera-equipped instruments inserted through minimal incisions, a laparoscopic surgeon can directly visualize the peritoneal surfaces, identify the distribution and character of tumor deposits, take targeted biopsies from representative sites, and estimate PCI based on direct inspection of all 13 peritoneal regions. The information gathered in a single laparoscopic procedure directly determines whether a patient proceeds to CRS-HIPEC, and if so, when and in what context.

CT- or ultrasound-guided core needle biopsy is used when laparoscopy is not feasible. Its primary limitation is sample size: needle biopsies yield less tissue than laparoscopic procedures, which reduces the ability to accurately characterize histological subtype and may miss areas across different tumor regions. In peritoneal mesothelioma, where the distinction between epithelioid and sarcomatoid components can determine surgical candidacy, an inadequate biopsy sample carries real clinical consequences.

Pathology: Confirming the Diagnosis

Once tissue is obtained, pathological analysis of peritoneal mesothelioma is more complex than for most other cancers because it must be distinguished from benign conditions and from a specific set of other malignancies that can produce identical-appearing peritoneal disease. The most important mimics are primary peritoneal carcinoma, ovarian serous carcinoma (particularly in women), colorectal and appendiceal metastases, and desmoplastic small round cell tumor.

Distinguishing peritoneal mesothelioma requires a targeted panel of immunohistochemical (IHC) stains applied by a pathologist with specific experience in peritoneal malignancies:

The pattern of positive calretinin, D2-40, and CK5/6 combined with negative BerEP4 and CEA is the core diagnostic signature of peritoneal mesothelioma. BAP1 loss (present in approximately 60–70% of epithelioid peritoneal mesothelioma cases) is a highly specific finding that essentially confirms the diagnosis when present.

This IHC panel must be interpreted by a pathologist with specific experience in peritoneal malignancies. Misclassification of peritoneal mesothelioma as ovarian carcinoma or primary peritoneal carcinoma is a documented and consequential error. If your diagnosis was made at a facility without specific mesothelioma or peritoneal disease expertise, a second pathology review of your biopsy slides at a major mesothelioma center is appropriate and often advisable before treatment begins.

Molecular Profiling: Beyond Standard Pathology

Current guidelines recommend comprehensive molecular tumor profiling as a standard component of peritoneal mesothelioma workup. The most clinically relevant findings include:

BAP1 mutation or loss — present in approximately 60–70% of epithelioid peritoneal mesothelioma, it is associated with longer survival independent of treatment and is being investigated as a predictive marker for response to EZH2 inhibitors.

CDKN2A deletion — more common in sarcomatoid and biphasic disease and associated with more aggressive behavior. Its presence affects prognostic counseling and may influence clinical trial eligibility.

Rare actionable alterations — NTRK fusions, ALK rearrangements, and ROS1 fusions are identified in a small minority of patients. When present, they may qualify those patients for approved targeted agents through histology-agnostic regulatory pathways.

If your treatment team has not discussed molecular profiling, ask about it explicitly before treatment begins. Tissue available at diagnosis may not be available later, and molecular information obtained early is more useful than molecular information sought after standard options have been exhausted.

How Peritoneal Mesothelioma Is Staged: The PCI and CC Systems

Peritoneal mesothelioma is not staged using the Tumor-Nodes-Metastasis (TNM) system used for most solid cancers. TNM staging was designed for cancers that form discrete masses and spread in predictable anatomical patterns. Peritoneal mesothelioma spreads differently: it grows diffusely across the lining of the abdominal cavity in sheets and nodules distributed across multiple regions simultaneously.

Two distinct scoring systems are used instead:

• The Peritoneal Cancer Index (PCI) measures how widely tumor has spread across the abdominal cavity and is assessed before or during surgical exploration. It is the primary determinant of whether a patient is a candidate for CRS-HIPEC.

• The Completeness of Cytoreduction (CC) score measures how much tumor remains after the cytoreductive surgery component of CRS-HIPEC. It is assessed during the procedure itself and is one of the strongest predictors of long-term outcomes.

The Peritoneal Cancer Index (PCI)

The PCI divides the abdominal cavity into 13 anatomical regions: nine regions covering the peritoneal surfaces of the abdomen (umbilical, right upper, epigastric, left upper, left flank, left lower, pelvis, right lower, and right flank) and four regions covering the small bowel and its mesentery (upper jejunum, lower jejunum, upper ileum, lower ileum). Each region is scored from 0 to 3 based on the size of the largest tumor nodule visible within it:

The scores from all 13 regions are added together, producing a total PCI from 0 to 39.

In peritoneal mesothelioma, the relationship between PCI and outcomes is more nuanced than in other peritoneal cancers. Mesothelioma patients with PCI scores above 20 can still achieve meaningful survival benefit from CRS-HIPEC when performed at high-volume centers, particularly in patients with epithelioid histology. The threshold is a guideline rather than a bright line, and individual anatomy, distribution of disease, and degree of small bowel involvement matter alongside the number itself.

PCI can be estimated from preoperative imaging — contrast-enhanced CT and diffusion-weighted MRI together provide the best non-invasive approximation — but imaging consistently underestimates true PCI, particularly for small-volume disease on bowel surfaces and the small bowel mesentery. For this reason, most major peritoneal mesothelioma centers use diagnostic laparoscopy to assess PCI directly before committing to open cytoreductive surgery.

The Completeness of Cytoreduction (CC) Score

While PCI determines who undergoes CRS-HIPEC, the CC score determines how much benefit they receive from it. Assessed by the surgeon immediately after completing the cytoreductive phase, the CC score measures the size of the largest remaining tumor deposit anywhere in the abdomen:

CC-0 and CC-1 are treated as functionally equivalent in peritoneal mesothelioma. Nodules of 2.5 millimeters or smaller fall within the penetration depth of the heated chemotherapy solution delivered during HIPEC, meaning the drug can reach and destroy residual microscopic disease at that scale. In major institutional series, patients achieving CC-0 or CC-1 cytoreduction have median survivals exceeding 40 months. Patients with CC-2 residual disease have median survivals closer to those of non-surgical patients receiving systemic chemotherapy — often under 15 months — despite having undergone a major operation.

What PCI and CC Mean Together

PCI predicts the probability of achieving complete cytoreduction. A patient with a PCI of 8 and epithelioid histology has a high probability that a skilled surgical team will be able to achieve CC-0 cytoreduction across all 13 peritoneal regions. A patient with a PCI of 28 and extensive small bowel involvement has a much lower probability.

This is why the assessment of surgical candidacy in peritoneal mesothelioma should always be made by a surgeon with specific high-volume experience in CRS-HIPEC for this disease — not by a community oncologist interpreting a CT report. Experienced surgeons at high-volume centers can achieve complete cytoreduction in cases that less experienced teams might judge unresectable, and they can make the intraoperative decisions that determine CC score with a judgment that comes only from having performed the procedure many times.

Extra-Abdominal Disease

Beyond PCI and CC scoring within the abdominal cavity, the presence of extra-abdominal metastatic disease significantly affects treatment planning. Distant metastases to the lung, liver parenchyma, bone, or distant lymph nodes indicate systemic disease that CRS-HIPEC cannot address, and their presence generally moves patients from a surgical to a systemic treatment approach. Preoperative staging should always include imaging sufficient to rule out significant extra-abdominal spread, and PET-CT is the most sensitive tool for this assessment.

What Your PCI Means for You

Two patients with identical PCI scores can have very different surgical candidacy based on the distribution of their disease, including how heavily the small bowel is involved and whether disease is concentrated in surgically accessible regions or distributed across areas that are technically difficult to completely cytoreduct. A PCI of 18 with most disease on the greater omentum and anterior peritoneal surface is a different surgical situation than a PCI of 18 with extensive small bowel mesentery involvement, even though the number is identical.

If you have been told you are not a surgical candidate — or if you are not sure whether your PCI and disease distribution have been assessed by a surgeon with specific peritoneal mesothelioma expertise — a consultation at a major HIPEC center is warranted before that conclusion is accepted. Call us at 833-4-ASBESTOS and we can help connect you with the right programs.

Understanding Your Cell Type: Histological Subtypes of Peritoneal Mesothelioma

Once a biopsy confirms peritoneal mesothelioma, the pathology report will identify the histological subtype — the specific type of cancer cells making up your tumor. In peritoneal mesothelioma, cell type is one of the strongest determinants of how the disease will behave, which treatments are most likely to work, whether you are a candidate for CRS-HIPEC, and what your prognosis looks like. It also directly affects clinical trial eligibility.

Peritoneal mesothelioma is classified into three primary subtypes — epithelioid, sarcomatoid, and biphasic — but the peritoneal disease spectrum also includes two low-grade variants, well-differentiated papillary mesothelioma (WDPM) and multicystic mesothelioma (MCM), that behave very differently from the primary subtypes.

The survival data in this section draws primarily from Chapel et al. 2021, a multi-institutional study of 225 peritoneal mesothelioma cases from 11 institutions across 6 countries — the largest and most rigorously analyzed peritoneal-specific pathological dataset published to date — supplemented by Liu et al. 2014 for architectural variants not separately tracked in Chapel.

Epithelioid Mesothelioma

Epithelioid is the most common subtype in peritoneal mesothelioma, accounting for approximately 75–80% of peritoneal cases (a higher proportion than in pleural disease) and carrying the most favorable prognosis. Epithelioid cells form recognizable structures resembling normal tissue architecture and respond better to both surgery and chemotherapy.

In the Chapel 2021 multi-institutional series, epithelioid peritoneal mesothelioma had a median overall survival of 39 months. Patients who underwent cytoreduction had a median survival of 57 months (38–75) versus 21 months (9–42) for those who did not.

Within epithelioid disease, two variables drive within-subtype variation more than any others:

Architectural pattern. Tubulopapillary epithelioid mesothelioma is the most favorable architectural variant. In the Chapel series, patients with predominantly tubulopapillary tumors had a median overall survival of 76 months (42–115), which is more than double the 32 months seen in patients with other architectural patterns. The solid architectural pattern is substantially less favorable. The deciduoid variant — characterized by large cells with abundant glassy cytoplasm, occurring almost exclusively in women and young patients — carries a more aggressive course than typical epithelioid disease, with median OS of 47.2 months in the Liu 2014 series.

Nuclear grading. Chapel 2021 validated a composite nuclear grading system combining nuclear pleomorphism (scored 1–3) and mitotic index (scored 1–3). The sum yields a total from 2 to 6, converted to a three-tier grade:

On multivariate analysis across 21 clinical and pathological parameters, nuclear grade was the single variable independently associated with both overall survival and disease-free survival. It outperformed PCI, sex, age, necrosis, BAP1 status, and every other parameter tested. The survival curve for grade III epithelioid mesothelioma is similar to that of biphasic mesothelioma — meaning a tumor classified as epithelioid by histotype but grade III by nuclear features behaves, in survival terms, like biphasic disease.

Ask your oncologist specifically whether nuclear grading has been performed on your biopsy. It is not universally reported in community pathology practices, but it is now the strongest prognostic tool in the peritoneal mesothelioma pathology toolkit.

Sarcomatoid Mesothelioma

Sarcomatoid mesothelioma accounts for approximately 5–10% of peritoneal cases and is the most aggressive subtype. In the Chapel series, the single sarcomatoid patient had a survival of 4 months, consistent with historical reports of median survival typically below 12 months in sarcomatoid peritoneal disease. The spindle-shaped, disorganized cells are highly invasive, express high levels of PD-L1, and are substantially more resistant to chemotherapy than epithelioid cells.

CRS-HIPEC is rarely appropriate for sarcomatoid peritoneal mesothelioma. The aggressive biological behavior means that even when complete cytoreduction is technically achievable, the rapid recurrence pattern typically negates the survival benefit that surgery delivers in epithelioid disease. Systemic therapy is the primary treatment approach. Immunotherapy with nivolumab-ipilimumab represents the most evidence-supported systemic option for this subtype.

Biphasic Mesothelioma

Biphasic mesothelioma contains both epithelioid and sarcomatoid cells within the same tumor and accounts for approximately 15–20% of peritoneal cases. In the Chapel 2021 series, biphasic peritoneal mesothelioma had a median overall survival of 14 months (4–71).

The ratio of epithelioid to sarcomatoid cells governs prognosis and treatment approach. Selected biphasic patients who underwent CRS-HIPEC in the Chapel series had a median OS of 63 months, compared to 12 months for those who did not, suggesting that CRS-HIPEC candidacy for biphasic disease should be evaluated individually at high-volume centers rather than refused categorically.

The biphasic classification also creates a specific diagnostic challenge: a small biopsy sample may not capture the full heterogeneity of a biphasic tumor, potentially misclassifying it as epithelioid. This is one of the strongest arguments for laparoscopic biopsy with multiple samples from different peritoneal regions over needle approaches.

Well-Differentiated Papillary Mesothelioma (WDPM)

Well-differentiated papillary mesothelioma is a distinct low-grade variant diagnosed almost exclusively in women of reproductive age, frequently incidentally during surgery for an unrelated condition. It is characterized by papillary projections covered with a single layer of well-differentiated mesothelial cells reflecting a genuinely less aggressive biology.

The Chapel 2021 series provides the most concrete survival data available for WDPM: a median overall survival of 185 months (82–185) — more than 15 years — compared to 39 months for high-grade epithelioid mesothelioma in the same dataset.

A patient with true WDPM does not require CRS-HIPEC on the same urgent timeline as a patient with high-grade epithelioid mesothelioma. WDPM can be misclassified as high-grade mesothelioma by pathologists without specific peritoneal disease experience, with the consequence of unnecessarily aggressive treatment recommendations for a disease that may not require them.

An important caveat: not all WDPM follows an indolent course. A small proportion of patients develop progressive disease, and transformation to high-grade mesothelioma has been documented. The favorable prognosis of WDPM is a basis for careful, ongoing monitoring at a center with specific expertise in this variant — not reassurance that the disease can be ignored.

Multicystic Mesothelioma (MCM)

Multicystic mesothelioma presents as multiple thin-walled translucent cysts arising from the peritoneal surfaces, most commonly in the pelvis, and is diagnosed almost exclusively in women of reproductive age, frequently as an incidental finding. Despite its historical classification as benign, MCM is now understood as a low-grade neoplasm because it recurs locally in approximately 50% of cases following surgical removal, and rare transformation to malignant mesothelioma has been documented. Patients with MCM require ongoing surveillance rather than discharge after surgery.

A Note on BAP1 in Peritoneal Mesothelioma

BAP1 loss (present in approximately 60–70% of epithelioid peritoneal mesothelioma cases) is highly specific for mesothelioma diagnosis and is one of the most useful IHC markers in the diagnostic panel. Its role as a prognostic marker in peritoneal disease, however, is more complicated than in pleural mesothelioma.

In pleural mesothelioma, BAP1 loss is generally associated with improved prognosis. In peritoneal mesothelioma, the Chapel 2021 data shows no meaningful prognostic difference between patients with and without BAP1 loss — median overall survival of 34 versus 36 months, respectively, a difference that was not statistically significant. BAP1 status in peritoneal mesothelioma is a diagnostic tool, not a reliable prognostic one, and should not be used to counsel patients on likely outcomes.

Why Your Cell Type Matters Beyond the Doctor's Office

Histological subtype and nuclear grade carry direct relevance to legal and financial claims as well. Life expectancy projections are central to how damages are calculated in mesothelioma cases, and they differ substantially across the subtypes and grades. A grade I tubulopapillary epithelioid patient and a grade III epithelioid patient carry survival distributions that, per the Chapel data, are nearly as different as epithelioid and biphasic disease. Accurate histological classification and nuclear grading are therefore clinical and legal priorities.

If your diagnosis was made at a facility without specific peritoneal mesothelioma pathology experience, or if nuclear grading has not been performed, a second review of your pathology slides at a major mesothelioma center is worth pursuing before treatment begins and before legal proceedings are initiated.

Peritoneal Mesothelioma in Women

Women represent a meaningfully higher proportion of peritoneal mesothelioma diagnoses than pleural diagnoses, and their experience with this disease differs from men's in several documented ways:

• Misdiagnosis is a significant and documented problem. Because peritoneal mesothelioma produces symptoms nearly identical to advanced ovarian cancer, women are frequently evaluated and treated along a gynecological oncology pathway for months before the correct diagnosis is reached.

• Specific histological variants occur predominantly in women. Well-differentiated papillary mesothelioma (WDPM), multicystic mesothelioma (MCM), and the deciduoid variant of epithelioid mesothelioma are all diagnosed almost exclusively in women, each with distinct clinical behavior and treatment implications.

• Talc exposure is a peritoneal-specific exposure pathway. Women without occupational or secondary asbestos exposure may have been exposed through long-term perineal use of talcum powder products containing asbestos contamination, which is a pathway associated specifically with peritoneal disease and the basis for legal claims against cosmetic product manufacturers distinct from traditional asbestos litigation.

For a full discussion of peritoneal mesothelioma in women — including the talc exposure pathway, histological variants specific to women, fertility considerations for younger patients, prognosis by sex, and legal options for women without occupational asbestos exposure — see our dedicated page:

Peritoneal Mesothelioma in Women: Diagnosis, Exposure, and Legal Options

Treating Peritoneal Mesothelioma: What to Know Before You Go Deeper

Peritoneal mesothelioma is not untreatable, and the options available today are meaningfully better than they were even a decade ago. For eligible patients, the cornerstone treatment is cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) — a procedure that surgically removes all visible tumor from the peritoneal surfaces and then delivers heated chemotherapy directly into the abdominal cavity to address microscopic residual disease.

In the largest and most current multi-center dataset, patients who underwent CRS-HIPEC had a median overall survival of 44.6 months and a one-year survival rate of 95% — compared to 11.2 months in patients who received systemic chemotherapy alone. For patients with low tumor burden and favorable histology, five-year and ten-year survival after CRS-HIPEC is documented in multiple institutional series.

Not every patient is a CRS-HIPEC candidate. Patients with high PCI scores, sarcomatoid or unfavorable biphasic histology, poor performance status, or significant comorbidities are managed primarily with systemic chemotherapy — typically pemetrexed combined with cisplatin or carboplatin. Immunotherapy with checkpoint inhibitors, particularly nivolumab combined with ipilimumab, has become an increasingly relevant option for patients with non-epithelioid histology, recurrent disease after surgery, or disease that has progressed on chemotherapy.

The most important structural point about peritoneal mesothelioma treatment is one that the survival data makes unavoidable: where you are treated matters more than in almost any other cancer. A direct comparison of academic medical center versus community hospital outcomes in peritoneal mesothelioma specifically found median survival of 24.8 months at academic centers versus 11.6 months at community hospitals. Academic centers were twice as likely to perform surgery and nearly three times more likely to use guideline-consistent chemotherapy.

For the full treatment discussion, including CRS-HIPEC in detail, chemotherapy regimens, immunotherapy, and how legal compensation funds the best available care, see our dedicated treatment page:

Peritoneal Mesothelioma: Treatment Options, Costs, and Prognosis in 2026

Prognosis for Peritoneal Mesothelioma

Peritoneal mesothelioma has a wide range of outcomes depending on the variables specific to each patient, and the distance between the best and worst ends of that range is larger than in almost any other cancer. A patient with low-PCI tubulopapillary epithelioid disease who undergoes complete cytoreduction at a major center has a realistic chance of living five, ten, or more years. A patient with high-PCI sarcomatoid disease managed with systemic chemotherapy at a community hospital has a median survival measured in months. The population average obscures that range almost entirely.

The Variables That Drive Outcomes

Treatment received and where. This is the dominant prognostic variable in peritoneal mesothelioma — larger in effect size than histology, PCI, or any other clinical factor. Patients who underwent CRS-HIPEC had a median overall survival of 44.6 months versus 11.2 months for those receiving systemic chemotherapy alone.

Histological subtype and nuclear grade. Epithelioid disease carries a median overall survival of 39 months; biphasic disease 14 months; sarcomatoid disease 4 months. Within epithelioid disease, nuclear grade refines this further: grade I tumors have a median OS of 58 months, grade II 32 months, and grade III 7 months. Tubulopapillary epithelioid tumors had a median OS of 76 months versus 32 months for other patterns.

Peritoneal Cancer Index. PCI below 10 at the time of surgery is associated with the highest likelihood of complete cytoreduction and the longest survival in CRS-HIPEC series. PCI above 27 is associated with substantially shorter survival even with surgery, and above 30 most patients are managed systemically.

Age and sex. Patients under 60 had a median overall survival of 58 months versus 25 months in patients 60 and older in the Chapel 2021 series. Within epithelioid disease, women had a median overall survival of 44 months compared to 34 months in men — a statistically significant difference that reflects a combination of biological and clinical factors including the higher proportion of favorable variants in the female peritoneal population.

Performance status. ECOG 0 or 1 at diagnosis was associated with a median OS of 62 months versus 21 months in patients with ECOG 2 or 3 in the Chapel series.

What the Numbers Say About CRS-HIPEC

For patients who undergo CRS-HIPEC with complete cytoreduction at a high-volume center, the median survival exceeds three years and five-year survival rates between 40% and 70% have been reported in well-selected cohorts with favorable histology. For patients with grade I tubulopapillary epithelioid disease and low PCI, median survival in the 76-month range reflects outcomes that would have been considered implausible for peritoneal mesothelioma two decades ago.

For patients with WDPM, the Chapel series reported a median overall survival of 185 months — a disease that behaves more like a chronic condition than a rapidly fatal cancer in most patients.

For non-surgical candidates receiving systemic chemotherapy as primary treatment, median survival is approximately 11 months in current series, with meaningful variation based on histology and response to treatment.

You Are Not a Statistic

Every year, patients with peritoneal mesothelioma live longer than the numbers predicted, usually because they found the right specialist, qualified for a clinical trial, responded durably to immunotherapy, or had disease characteristics that placed them at the favorable end of a wide distribution. What you can do is make the decisions that give you the best chance of being one of those patients: getting to a center with specific peritoneal mesothelioma expertise, ensuring your histology has been accurately characterized and nuclear grade assessed, and securing the financial resources that make the best available care accessible rather than theoretical.

Living with Peritoneal Mesothelioma

Managing Physical Symptoms

The physical symptoms of peritoneal mesothelioma — abdominal pain, distension, nausea, fatigue, and the complications of ascites — can be treated, often very effectively, through palliative care that runs alongside whatever primary treatment you are receiving.

Palliative care is not the same as hospice. It does not mean giving up on treatment or accepting that the end is near. It means treating symptoms as aggressively as the disease itself, using every available tool to keep you comfortable, functional, and in control of your daily life. A good palliative care team can manage pain precisely, perform paracentesis to drain ascites and relieve abdominal pressure, adjust medications to reduce nausea, and address the fatigue and sleep disruption that accompany active disease.

For patients who undergo CRS-HIPEC, the physical recovery is significant and deserves honest framing. The procedure involves major abdominal surgery lasting anywhere from six to twelve hours, followed by an ICU stay and a total hospitalization averaging nine days. Returning to normal activity typically takes four to eight weeks after discharge, and full functional recovery often takes three to six months. Many patients describe the weeks immediately after surgery as harder than they expected, even when the procedure went well. That experience is normal, not a sign that something went wrong.

Nutrition and Digestive Health

Nutrition occupies a more central role in peritoneal mesothelioma than in most other cancers because the disease and its treatment both directly affect the gastrointestinal system. Before treatment, ascites and tumor bulk pressing on the stomach and bowel can cause early satiety, nausea, and reduced appetite at the same time the cancer is increasing the body's metabolic demands. After CRS-HIPEC — particularly when bowel resection has been part of the procedure — patients face a digestive adjustment period that can include altered motility, dietary intolerances, and changes in how the body absorbs nutrients.

Working with a nutritionist or registered dietitian with oncology experience can make a meaningful practical difference. Small, frequent meals are typically easier to tolerate than standard-sized meals. Calorie-dense foods help maintain weight when appetite is reduced. Adequate nutrition supports treatment tolerance, recovery speed, immune function, and overall wellbeing throughout the disease course.

Movement and Physical Rehabilitation

The instinct to rest completely during and after cancer treatment is understandable, but sustained inactivity typically makes fatigue worse rather than better. For peritoneal mesothelioma patients, particularly those recovering from CRS-HIPEC, structured physical rehabilitation has documented benefits for fatigue, functional recovery, and psychological wellbeing. Walk when you can. Build gradually. Ask your care team about a supervised exercise program appropriate to your current functional status.

The Emotional Weight

The emotional experience of a peritoneal mesothelioma diagnosis does not follow a clean sequence of stages. Fear, grief, anger, and acceptance arrive in no particular order, sometimes simultaneously, and often in response to things that seem small from the outside, like a follow-up scan or a bad week of fatigue.

For younger patients — and peritoneal mesothelioma is diagnosed at younger ages than pleural disease, with a meaningful proportion of patients in their forties and fifties — the diagnosis arrives at a life stage where the practical consequences are particularly acute: careers interrupted, children still at home, decades of life expected ahead.

Support groups connect you with people who are actually living what you are living. Both in-person and online groups exist specifically for mesothelioma patients and families. Counseling and therapy offer professional help processing the weight of a life-changing diagnosis, building coping strategies, and managing anxiety and depression. Spiritual and contemplative practices — meditation, prayer, journaling, and time in nature — can provide grounding when the situation feels out of control.

For Caregivers

Caregivers carry a disproportionate and often invisible burden. If you are a caregiver, your needs matter. Respite care (short-term relief from caregiving responsibilities) exists precisely because sustainable caregiving requires rest.

The recovery period after CRS-HIPEC places particular demands on caregivers. The patient will need significant assistance for weeks after discharge, and the extended recovery timeline can stretch caregiver capacity in ways that require planning in advance. Discussing what support will be needed after discharge should happen before the procedure, not after. The social worker attached to most major peritoneal mesothelioma programs can help coordinate resources, connect you with community support, and provide guidance that makes the recovery period more manageable for everyone involved.

Legal Options for Families Affected by Peritoneal Mesothelioma

CRS-HIPEC at a major academic center, combined with neoadjuvant and adjuvant chemotherapy and the follow-up surveillance that comes afterward, commonly exceeds $300,000 in total treatment costs. Insurance covers some of it, but it rarely covers all of it. Travel to a major center, lodging during treatment, uncovered medications, lost income, and in-home caregiving during recovery accumulate quickly on top of direct medical costs.

That financial strain is not a neutral fact of life. The companies that manufactured, sold, and profited from asbestos long after their own research confirmed it caused cancer made a deliberate decision that their profits were worth more than your health. The financial burden you are navigating is part of the cost of that decision.

Legal compensation, asbestos trust fund claims, VA benefits for veterans, and disability programs exist specifically to shift that cost back where it belongs. They are tools of accountability, and they can make the difference between accessing the best care available and making do with what insurance approves.

Asbestos Trust Fund Claims

When major asbestos manufacturers filed for bankruptcy under the weight of mounting litigation, courts required them to establish compensation trusts with dedicated funds set aside to pay current and future victims. More than 60 of these trusts exist today, collectively holding billions of dollars. Trust fund claims do not require a lawsuit or a courtroom. They are handled on paper, based on documented evidence of exposure and diagnosis. For mesothelioma patients, claims are typically prioritized and expedited — in many cases we secure initial payments within 30 days of filing. Most clients qualify for claims against multiple trusts.

Learn more about asbestos trust fund claims.

Mesothelioma Lawsuits

When the responsible company is still operating, a personal injury lawsuit may be appropriate and can result in compensation substantially beyond what trust funds pay. Most mesothelioma cases settle before trial. For families who have lost someone to peritoneal mesothelioma, wrongful death claims follow the same general framework. There are no caps on medical expense damages in mesothelioma cases — the full cost of CRS-HIPEC, chemotherapy, immunotherapy, travel to major centers, and long-term follow-up care is recoverable.

Learn more about mesothelioma lawsuits.

Talc Litigation

Talc litigation applies to women who developed peritoneal mesothelioma through long-term perineal use of talcum powder products containing asbestos contamination. These claims are legally and factually distinct from traditional asbestos litigation. The defendants are cosmetic and personal care product manufacturers rather than industrial asbestos producers. The legal theory is product liability, which holds that manufacturers are liable for failing to test, disclose, or reformulate products they knew or should have known contained asbestos.

Talc claims can be pursued simultaneously and in addition to any asbestos trust fund or personal injury claims arising from other exposure pathways. They are not mutually exclusive. Total compensation across all applicable pathways can be substantially higher than any single track would produce.

Learn more about talc litigation and peritoneal mesothelioma.

VA Benefits for Veterans

Veterans are among the groups most severely affected by mesothelioma. If you served and have been diagnosed with peritoneal mesothelioma, you may be entitled to VA disability compensation and full VA healthcare coverage for treatment including CRS-HIPEC at VA-affiliated centers. VA benefits can be pursued alongside trust fund claims, lawsuits, and talc litigation without affecting eligibility for any of them.

Learn more about VA benefits for mesothelioma.

Social Security Disability (SSDI)

Peritoneal mesothelioma is one of a small number of conditions included in the Social Security Administration's Compassionate Allowances program, which fast-tracks disability benefit approval for people with serious diagnoses. Benefits can be approved within weeks rather than the months or years standard applications typically take. Approved SSDI also accelerates Medicare eligibility — which matters when treatment costs are mounting and insurance gaps are significant.

Learn more about SSDI for mesothelioma.

Statute of Limitations: Why Timing Matters

Every state sets a filing deadline (the statute of limitations) for mesothelioma claims. In most states, the clock begins running from the date of diagnosis rather than the date of exposure. But the deadline is real, and in some states it arrives faster than people expect. Waiting months to consult an attorney while focusing on treatment decisions is understandable, but it can foreclose legal options that would otherwise be available.

A consultation costs nothing and obligates you to nothing. It takes less time than most medical appointments. And the information it produces — which claims apply to your situation, what compensation is realistically available, what documentation to start gathering now — is useful immediately, regardless of when or whether you decide to proceed.

The compensation available through these legal pathways often funds travel to a high-volume CRS-HIPEC center when the nearest one is 800 miles away. It pays for the immunotherapy session insurance denied. It covers the extended post-surgical home health care that makes recovery at home possible. It replaces income that stopped when treatment made working impossible.

That is why the legal discussion belongs on a medical page, and why pursuing your legal options is not a separate project from pursuing the best available treatment. They are the same project.

About Our Firm

The Law Offices of Justinian C. Lane, Esq. – PLLC has recovered more than $400 million for asbestos victims since 2014. Our founding attorney lost his father, grandfather, and grandmother to asbestos-related cancers and is himself a cancer survivor. We work with medical experts who specialize in this disease, and we can help ensure your pathology has been interpreted by someone with the right expertise.

We represent mesothelioma patients and their families nationwide, with offices in Texas, Arizona, California, and Washington. We work on a contingency fee basis with no upfront costs and no fees unless we recover compensation for you.

Take the Next Step

You have already faced more than your share of hard things. Let us handle the fight for accountability while you focus on what matters most.

Call us today at 833-4-ASBESTOS (833-427-2378) or schedule your free consultation online. No cost. No pressure. Just honest answers and a clear path forward.

You did not ask for this diagnosis — but you can choose how you respond to it. You have rights. You have options. And we are here to make sure you can use both.

References

1. Yaşar S, Yılmaz F, Utkan G, et al. Analysis of treatment strategies and outcomes in malignant peritoneal mesothelioma: insights from a multi-center study. Ann Surg Oncol. 2024;31(9):6228–6236. doi:10.1245/s10434-024-15506-3

2. Malpica A, Euscher ED, Marques-Piubelli ML, et al. Malignant mesothelioma of the peritoneum in women: a clinicopathologic study of 164 cases. Am J Surg Pathol. 2020;44(6):782–798. doi:10.1097/PAS.0000000000001445

3. Liu S, Staats P, Lee M, Alexander HR, Burke AP. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients. Pathology. 2014;46(7):604–609. doi:10.1097/PAT.0000000000000181

4. Brandl A, Westbrook S, Nunn S, et al. Clinical and surgical outcomes of patients with peritoneal mesothelioma discussed at a monthly national multidisciplinary team video-conference meeting. BJS Open. 2020;4(2):260–267. doi:10.1002/bjs5.50256

5. Kusamura S, Kepenekian V, Villeneuve L, et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2021;47(1):36–59. doi:10.1016/j.ejso.2020.02.011

6. Welten VM, Fields AC, Malizia RA, et al. Survival outcomes for malignant peritoneal mesothelioma at academic versus community hospitals. J Gastrointest Surg. 2022;26(1):161–170. doi:10.1007/s11605-021-05084-0

7. Chapel DB, Schulte JJ, Absenger G, et al. Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. Mod Pathol. 2021;34(2):380–395. doi:10.1038/s41379-020-00688-4